Shu is first expert from Asia to receive the award. According to ARO, Shu was awarded for his collaborative and continued ...

The Audiogene trial is designed to evaluate the safety, tolerability and efficacy of intra-cochlear injection of SENS-501 for the treatment of OTOF gene-mediated hearing loss in paediatric patients ...

The Audiogene trial is designed to evaluate the safety, tolerability and efficacy of intra-cochlear injection of SENS-501 for the treatment of OTOF gene-mediated hearing loss in paediatric ...

SENS-501: Gene therapy program to restore hearing in OTOF patients Sensorion’s SENS-501 dual vector AAV (adeno-associated virus) gene therapy development product aims at restoring hearing in ...

As presented at ARO, 10 of 11 children with at least one post-treatment assessment showed notable improvements in hearing TARRYTOWN, N.Y., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Regeneron ...

At the start of 2024, Eli Lilly shared data that tied its investigational therapy, known as AK-OTOF, to restored hearing in one child who had experienced hearing loss since birth. The Akouos ...

However, otoferlin-related hearing loss is ultra-rare. This specific condition is caused by variants in the OTOF gene, which leads to a lack of a functional otoferlin protein that is critical for ...

It is caused by variants in the OTOF gene, which lead to a lack of a functional otoferlin protein critical for communication between the inner ear’s sensory cells and the auditory nerve.

adds to growing evidence of the efficacy of such treatments in children who have profound deafness caused by mutations of the OTOF (otoferlin) gene. "It's an ultra rare condition," said Jonathon ...

In addition to OTOF, Regeneron is committed to investigating several other targets for genetic forms of hearing loss, including GJB2. Regeneron (NASDAQ: REGN) is a leading biotechnology company ...

SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to ...